Biogen (NASDAQ:BIIB) Stock Rating Upgraded by JPMorgan Chase & Co.

Posted by Stanley Muller on Oct 14th, 2026

Biogen (NASDAQ:BIIB – Get Free Report) was upgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm currently has a $300.00 target price on the biotechnology company’s stock, up from their previous target price of $210.00. JPMorgan Chase & Co.‘s target price suggests a potential upside of 31.06% from the company’s current price.

Several other research firms have also recently commented on BIIB. Oppenheimer reissued an “outperform” rating and set a $300.00 target price on shares of Biogen in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Barclays upped their price target on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 29th. Royal Bank Of Canada decreased their price objective on shares of Biogen from $260.00 to $256.00 and set an “outperform” rating for the company in a report on Thursday, October 8th. Finally, Needham & Company LLC raised their price objective on shares of Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $236.04.

Get Our Latest Analysis on Biogen

Biogen Trading Down 0.2%

NASDAQ:BIIB opened at $228.90 on Monday. Biogen has a 1 year low of $138.00 and a 1 year high of $238.24. The stock has a market cap of $33.82 billion, a price-to-earnings ratio of 16.42, a PEG ratio of 2.53 and a beta of 0.09. The business has a fifty day moving average of $218.37 and a 200-day moving average of $203.00. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87.

Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same period last year, the company earned $5.47 earnings per share. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts predict that Biogen will post 12.41 earnings per share for the current year.

Institutional Investors Weigh In On Biogen

Several hedge funds and other institutional investors have recently bought and sold shares of BIIB. Bell Investment Advisors Inc acquired a new stake in Biogen during the 2nd quarter worth about $27,000. Reflection Asset Management purchased a new position in Biogen during the 4th quarter valued at about $25,000. MV Capital Management Inc. acquired a new position in shares of Biogen in the 4th quarter valued at about $34,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Biogen in the 1st quarter valued at about $40,000. Finally, SHP Wealth Management purchased a new stake in shares of Biogen in the fourth quarter worth approximately $39,000. 87.93% of the stock is currently owned by institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

Positive Sentiment: JPMorgan upgraded Biogen to Overweight from Neutral and raised its price target to $300 from $210. The firm cited an increasingly compelling catalyst path, including expected 2027 clinical readouts for felzartamab and litifilimab. The target implies meaningful upside from recent trading levels. JPMorgan upgrade and price target article
Positive Sentiment: Litifilimab’s 52-week Phase 2 data in cutaneous lupus erythematosus supported the company’s immunology pipeline. The AMETHYST study showed sustained improvements in skin disease activity and a generally well-tolerated safety profile. FDA Breakthrough Therapy designation further strengthens the drug’s potential, although additional development remains necessary. Litifilimab 52-week data article
Neutral Sentiment: Citi maintained a Hold rating on Biogen. The stance provides a counterweight to JPMorgan’s upgrade and suggests some analysts believe the recent rally and pipeline optimism may already be reflected in the shares. Citi maintains Hold rating article
Negative Sentiment: Biogen’s upcoming third-quarter results are expected to show a sharp double-digit EPS decline. This earnings risk is limiting the impact of the bullish pipeline news ahead of the company’s scheduled October 28 report. Biogen quarterly earnings preview article

Biogen Company Profile

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.